Parkure’s pipeline news: two drugs pre-clicanically validated.

Two key pipeline compounds discovered by Parkure have been pre-clinically validated as part of a collaboration with Charles River Laboratories. Both drugs were found to rescue the symptoms of a virally induced rat model of Parkinson’s disease.

Beyond the progress for Parkure’s pipeline the results are indicative of the translational power of Parkure’s platform and it’s ability to discover drugs that act on validated Parkinson’s disease drug targets. The two drugs in question are repurposed but Parkure has already synthesised and tested novel chemical derivatives with very encouraging results.

Author: Lysimachos Zografos

CEO of Parkure Ltd.

Comments are closed.